HER2-targeted therapies in cancer: a systematic review
Feb 2, 2024 · This article, provides a comprehensive review of the underlying mechanism of action, representative drugs, corresponding clinical trials, recent advancements, and future research …
HER2-Positive Breast Cancer Clinical Trials - Mayo Clinic Research
The purpose of this study is to determine the correlation between HER2 specific T-cell response in HER2-positive breast cancer patients with stage I-IV who receive anti-HER2 therapies, such as …
Current research status on HER2 protein expression levels and the ...
Jun 30, 2025 · The review focuses on analyzing, synthesizing, and summarizing data from multiple rigorous, high-evidence-level large-scale clinical studies, particularly the IHC 3+ and IHC 2+ …
Silver Jubilee of HER2 targeting: a clinical success in breast cancer
Aug 1, 2025 · Even for tumors with HER2 mutations or low expressions, anti-HER2 therapies can still be effective. Newer treatments, like bispecific antibodies and vaccines, are being tested in clinical trials …
Conundrums in Treating HER2-Positive Early Breast Cancer
Jun 10, 2025 · The 2024 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for stage I disease state that for both hormone receptor–positive or …
HER2-targeted therapies beyond breast cancer — an update
Jul 22, 2024 · Over the past few years, the indications for HER2-targeted therapy have expanded beyond breast cancer and gastric or gastroesophageal junction cancer (G/GEJC) to include various …
New Drug Combination Improves Survival for ER+, HER2- Breast Cancer
May 31, 2025 · Inavolisib Triplet Therapy Clinical Trial Results Now a phase 3 clinical trial has shown that a new three-drug combination enabled ER-positive, HER2-negative breast cancer patients to …
DESTINY-Breast11 Trial Shows Enhertu Plus THP Significantly Improves ...
May 7, 2025 · Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab, and pertuzumab significantly …
HER2-Positive Breast Cancer Clinical Trials | Moffitt
HER2-positive breast cancer can become resistant to the beneficial effects of standard therapies over time. Read about the progress of ongoing clinical trials.
Study Details | NCT07307287 - ClinicalTrials.gov
Dec 29, 2025 · SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study …